Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
0.203
-0.021 (-9.15%)
Nov 21, 2024, 1:14 PM EST - Market open
Mainz Biomed Stock Forecast
MYNZ's stock price has decreased by -82.33% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Mainz Biomed stock has a target of 3.00, which predicts an increase of 1,374.93% from the current stock price of 0.20.
Analyst Consensus: Buy
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for Mainz Biomed stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +1,374.93% | Mar 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 21, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $9 → $5 | Strong Buy | Maintains | $9 → $5 | +2,358.21% | Nov 20, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $9 | Buy | Reiterates | $9 | +4,324.78% | Sep 26, 2023 |
Financial Forecast
Revenue This Year
1.22M
from 895.48K
Increased by 36.69%
Revenue Next Year
2.35M
from 1.22M
Increased by 91.67%
EPS This Year
-0.89
from -1.62
EPS Next Year
-0.75
from -0.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.4M | 2.4M | 9.7M | ||
| Avg | 1.2M | 2.3M | 9.4M | ||
| Low | 1.1M | 2.3M | 9.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.4% | 97.3% | 311.8% | ||
| Avg | 36.7% | 91.7% | 300.0% | ||
| Low | 20.4% | 84.2% | 284.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.88 | -0.78 | -0.68 | ||
| Avg | -0.89 | -0.75 | -0.66 | ||
| Low | -0.89 | -0.73 | -0.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.